Prof. Mehmet Haberal is presented with The Award of The Spanish Order of The Civil Merit (Cruz de Official) by His Majesty King Felipe VI, King of Spain.
We are honored to announce that Prof. Dr. Seza Özen who is the member of Honorary Advisory Board of JBACHS has already won the Aziz Sancar Science Award of TUSEB.
We are happy to announce that The Journal of Basic and Clinical Health Sciences (JBACHS) is indexed by the Emerging Sources Citation Index since November 2017, and indexed by the Ulakbim-TR since 2017.
Journal of Basic and Clinical Health Sciences 2020 , Vol 4 , Issue 3
Casticin: A Promising Candidate to Develop a Stem Cell Targeted Strategy in AML Treatment
Tugba Erkmen1,Belgin Sert Serdar1,Halil Ates2,Pembe Keskinoglu3,Semra Kocturk4
1Dokuz Eylul University, Health Sciences Institute, Izmir, Turkey
2Dokuz Eylul University, Oncology Institute, Izmir, Turkey
3Dokuz Eylul University, Department of Public Health, Izmir, Turkey
4Dokuz Eylul University, Department of Biochemistry, Izmir, Turkey
DOI : 10.30621/jbachs.2020.1226 Purpose: Acute myeloid leukemia is the most common form of acute leukemia with genetic and epigenetic heterogeneity. Although current therapeutic agents provide successful remission, 5-year survival rates are still low. Insufficiency of targeting leukemia stem cells is considered as the main obstacle that causes drug resistance and relapse. Phytochemicals remain a promising source for targeted drug research. Studies showed that Casticin has antiproliferative effects on leukemic cells, but its effects on leukemic stem cells are still unclear. In this study, we aimed to investigate the antiproliferative capacity of Casticin on acute myeloid leukemia stem-like (KG1a) cells and its relatively mature parental (KG1) cells in comparison with healthy peripheral blood mononuclear cells (PBMC).

Method: The antiproliferative effects of Casticin on cells and IC50 values were determined by MTT test. The effects of Casticin on caspase 3/7 activity, apoptosis and necrosis in cells were evaluated by flow cytometry and TUNEL assays.

Results: 2 μM Casticin treatment for 24 h was increased apoptotic cell death and caspase 3/7 activation in KG1 (27.2%; 17.30%; p<0.01) and KG1a (21.6%; 11.35%; p<0.01) with relatively low necrosis (1.4% and 0.3%) compared to their control groups. TUNEL assay also confirmed Casticin-induced apoptosis in KG1 (22.3%; p<0.05) and KG1a cells (19.03%; p<0.05) compared to their control groups. Additionally, there were no significant changes in apoptosis (10.6%), caspase 3/7 activity (0.24%), necrosis (0.6%) of PBMC group compared to its control group.

Conclusion: Casticin has the capacity to induce apoptosis in both leukemia stem-like and parental leukemic cells without significantly affecting healthy cells. Therefore, we think that Casticin can be a promising compound to develop novel therapeutic strategies for final AML treatment. Keywords : apoptosis, acute myeloid leukemia, Casticin, cancer stem cells